Efficacy and Safety in the Continued Treatment With a Biosimilar Drug in Patients Receiving Infliximab: A Systematic Review in the Context of Decision-Making From a Latin-American Country
Open Access
- 15 November 2019
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 10, 1010
Abstract
Introduction: Biological products, including infliximab (INF), are a therapeutic option for various medical conditions. In the Peruvian Social Security (EsSalud), infliximab is approved for the treatment of rheumatoid arthritis, psoriasis, psoriatic arthropathy, ankylosing spondylitis, ulcerative colitis and Crohn’s disease (in cases refractory to conventional treatment). Biosimilars are a safe and effective alternative approved for these diseases in patients who start treatment with infliximab. Nevertheless, there are people in treatment with the biological reference product (BRP), in whom the continuing therapy with a biosimilar biological product (BBP) must be evaluated. Objectives: To synthesize the best available evidence, calculate a preliminary financial impact and conduct technical discussions about the interchangeability into biosimilar in patients receiving treatment with original infliximab for medical conditions approved in EsSalud. Methodology: We carried out a systematic review of controlled clinical trials. Primary search was performed in Pubmed- MEDLINE, SCOPUS, WOS, EMBASE, TRIPDATABASE, DARE, Cochrane Library, NICE, AHRQ, SMC, McMaster-PLUS, CADTH, and HSE until June-2018. We used the Cochrane Collaboration tool to assess the risk of bias. Also, we implemented a preliminary financial analysis about the impact of biosimilar introduction on institutional purchasing budget. Moreover, technical meetings with medical doctors specialized in rheumatology, gastroenterology and dermatology were held for discussing findings. Results: In primary search, 1136 records were identified, and 357 duplicates were removed. From 799 records, we excluded 765 after title and abstract evaluation. From 14 full-text appraised documents, we included five clinical trials in the risk of bias assessment: four studies evaluated CTP-13 and one tested SB2. Two double-blind clinical trials reported no differences in efficacy and safety profiles between maintenance group (INF/INF) and interchangeability group in all diseases included (INF/CTP-13) and rheumatoid arthritis (CTP13 and SB2). In the other three studies, open-label extension of primary clinical trials, no differences were founded in efficacy and safety profiles between CTP-13/CTP-13 and INF/CTP-13 groups. In financial analysis, the inclusion of biosimilars implied savings around S/7´642,780.00 (1USD=S/3.30) on purchasing budget of EsSalud. In technical meetings, beyond certain concerns, specialists agreed with the findings. Conclusions: Evidence from clinical trials support that there are no differences in efficacy or safety of continuing the treatment with Infliximab BRP or exchanging into its biosimilar in patients with medical conditions approved in EsSalud. Financial analysis shows that the biosimilar introduction produce savings in purchasing institutional budget. Therefore, based on cost-opportunity principle, exchanging into biosimilar in patients receiving the original Infliximab, is a valid therapeutic alternative in the Peruvian Social Security.Keywords
This publication has 60 references indexed in Scilit:
- The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: A systematic review and meta-analysisSeminars in Arthritis and Rheumatism, 2014
- Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and surveyHealth Technology Assessment, 2014
- The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analysesClinical Microbiology and Infection, 2014
- The Spanish SF-36 in PeruAsia Pacific Journal of Public Health, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Los estudios de síntesis como base para las evaluaciones económicas: necesidad de la valoración de su calidadRevista Peruana de Medicina Experimental Y Salud Pública, 2011
- Review of regulation of biological and biotechnological products in Latin American and Caribbean countriesBiologicals, 2009
- How do the EQ-5D, SF-6D and the well-being rating scale compare in patients with ankylosing spondylitis?Annals of the Rheumatic Diseases, 2007
- Subgroup analyses in randomized trials: risks of subgroup-specific analyses;Journal of Clinical Epidemiology, 2004
- Subgroup analysis and other (mis)uses of baseline data in clinical trialsThe Lancet, 2000